SCHEMBL17625713

SCHEMBL17625713

C=C(C)C(=C)Oc1cc(-c2ccc(OC(=O)C(=C)C)cc2)ccc1-c1ccc(OC(=O)C(=C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 4/20 0.46
ELANE P08246 1/20 0.44
KMT2A Q03164 2/20 0.42
ATM Q13315 1/20 0.42
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
HSD17B1 P14061 1/20 0.36
HSD17B2 P37059 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
KDM4E B2RXH2 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
MAPT P10636 3/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
EGFR P00533 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22082356 0.97 BACE1 (0.46) BACE1ELANEKMT2AATMLMNA
SCHEMBL17625690 0.94 ELANE (0.49) BACE1ELANEKMT2AATMLMNA
SCHEMBL17625682 0.94 ELANE (0.49) BACE1ELANEKMT2AATMLMNA
SCHEMBL17625852 0.94 ELANE (0.49) BACE1ELANEKMT2AATMLMNA
SCHEMBL17625827 0.93 ELANE (0.48) BACE1ELANEKMT2AATMLMNA
SCHEMBL20922991 0.91 BACE1 (0.39) BACE1ELANEKMT2AATMLMNA
SCHEMBL25945052 0.90 BACE1 (0.47) BACE1ELANEKMT2AATMSMN1; SMN2
SCHEMBL17625853 0.89 ELANE (0.47) BACE1ELANEKMT2AATMLMNA
SCHEMBL17433313 0.88 ELANE (0.49) BACE1ELANEKMT2AATMLMNA
SCHEMBL16641176 0.88 HSD17B1 (0.44) BACE1ELANEKMT2AATMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3020700-B1 POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC CORP (JP) 2019-04-24 EP disclosed
US-20160152895-A1 POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2016-06-02 US disclosed
US-20160152895-A1 POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2016-06-02 US disclosed
EP-3020700-A1 POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC Corporation (JP) 2016-05-18 EP disclosed
WO-2015004947-A1 POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC株式会社 (JP) 2015-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152895-A1 POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE CCDC47, NCAPD2, CCDC22 BACE1 3961/4885ELANE 2827/4885KMT2A 3586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.